The parallel sessions are grouped in 3 different themes:

1. Chemical Biology
2. Drug Discovery Projects
3. Technologies

In addition, the programme contains five open sessions: First Time Disclosures (I & II), Late Breaking News/Recent Developments, Highlights in Medicinal Chemistry as well as a special session on Early Career Women in Medicinal Chemistry & Chemical Biology. For these sessions, the talks will be selected from the submitted abstracts.

For most of the below topics, two slots in the programme will be available for an oral communication selected out of the submitted abstracts.

Chemical Biology

• Small Molecule Treatments for Protein Misfolding Diseases
  Chair: Dr Mark Bunnage, Vertex Pharmaceuticals, US
  
  
• Tackling “Difficult-to-Drug”-Targets with Chemical Biology Approaches
  Chair: Dr Jacob Bush, GlaxoSmithKline, UK
             
• Bio-orthogonal Synthetic Chemistry (AFMC Session)
  Chairs: Prof. Youngjoo Byun, Korea University, KR & Prof. Sun-Joon Min, Hanyang University, KR
  
  
• Targeting RNA and RNA-modifying Enzymes
  Chair: Dr Matthew Fyfe, Storm Therapeutics, UK
  
  
• Solute Carrier Protein (SLC) Transporters as Targets for Drug Discovery
  Chair: Dr Andreas Gollner, Solgate, AT

• Chemical Induced Proximity Approaches for Therapeutic Intervention
  Chair: Dr Gregory Hollingworth, Novartis, CH
  
  
• Targeting RAS (ICBS Session)
  Chair: Prof. Zaneta Nikolovska-Coleska, University of Michigan, US
  
  

Drug Discovery Projects

• Drug Discovery Beyong the Rule of Five 
  Chair: Prof. Iwan De Esch, Vrije Universiteit Amsterdam, NL
  
  
• Chemical Strategies to Modulate Neuroinflammation (ACSMEDI Session)
  Chair: Prof. Nadia German, Texas Tech University Health Sciences Center, US
  
  
• Trends in Peptide Drug Discovery
  Chair: Prof. Gilles Guichard, University of Bordeaux, FR
  
  
• Advances in Immuno-oncology Therapy with Small Molecule Inhibitors
  Chair: Dr Pravin Iyer, TBC (Glenmark Pharmaceuticals), IN
  
  
• Impact of Cryo-EM in Drug Discovery
  Chair: Dr Herbert Nar, Boehringer Ingelheim, DE
  
  
• Early Integration of Translational Strategies into Discovery Projects
  Chair: Dr Antonia Stepan, F. Hoffmann-La Roche, CH
  
  
• Addressing Unmet Needs on Emerging and Re-emerging Infectious Diseases
  Chair: Prof. Vincenzo Summa, University of Naples, IT
  
  

Technologies

• Novel Methodologies in Photo- and Electrochemistry
  Chair: Dr Lisa Candish, Bayer, DE
  
  
• Reality Check “AI in Drug Design” – State of the Art or Fiction - an EFMC² session
  Chairs: Dr Werngard Czechtizky, AstraZeneca, SE & Dr Nadine Schneider, Novartis, CH
  
  
• Computational Chemistry and Computational Biology in Drug Discovery
  Chair: Prof. Marco De Vivo, Istituto Italiano di Tecnologia, IT
  
  
• New Technologies for the Discovery of Protein Degraders (CPA Session)
  Chair: Prof. Ke Ding, Jinan University, CN
  
  
• Sustainability – Green Chemistry
  Chair: Álvaro Enríquez García, Eli Lilly and Company, ES
  
  
• DNA-Encoded Libraries (ACSMEDI Session)
  Chair: Prof. Amanda Garner, University of Michigan, US
  
  
• Biomimetic Drug Delivery Systems (EuChems Session)
  Chair: Prof. Francesco Peri, University of Milano/Bicocca, IT
  
  

Special Session (selected from submitted abstracts)

• Early Career Women in Medicinal Chemistry & Chemical Biology
  Chairs: Dr Maria-Jesús Blanco, Atavistik Bio, US & Prof. Maria Laura Bolognesi, University of Bologna, IT
  
  

Open Sessions (selected from submitted abstracts)